BIOCELTIX S.A. ZY -10 (XI3) - Net Assets
Based on the latest financial reports, BIOCELTIX S.A. ZY -10 (XI3) has net assets worth €73.28 Million EUR (≈ $85.67 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€75.63 Million ≈ $88.42 Million USD) and total liabilities (€2.36 Million ≈ $2.75 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read BIOCELTIX S.A. ZY -10 debt and liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €73.28 Million |
| % of Total Assets | 96.89% |
| Annual Growth Rate | 86.94% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 100.6 |
BIOCELTIX S.A. ZY -10 - Net Assets Trend (2021–2025)
This chart illustrates how BIOCELTIX S.A. ZY -10's net assets have evolved over time, based on quarterly financial data. Also explore XI3 asset base for the complete picture of this company's asset base.
Annual Net Assets for BIOCELTIX S.A. ZY -10 (2021–2025)
The table below shows the annual net assets of BIOCELTIX S.A. ZY -10 from 2021 to 2025. For live valuation and market cap data, see XI3 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €73.28 Million ≈ $85.67 Million |
+90.73% |
| 2024-12-31 | €38.42 Million ≈ $44.91 Million |
+267.05% |
| 2023-12-31 | €10.47 Million ≈ $12.24 Million |
+103.20% |
| 2022-12-31 | €5.15 Million ≈ $6.02 Million |
-14.15% |
| 2021-12-31 | €6.00 Million ≈ $7.01 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BIOCELTIX S.A. ZY -10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 532771686.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €88.07 Million | 120.19% |
| Total Equity | €73.28 Million | 100.00% |
BIOCELTIX S.A. ZY -10 Competitors by Market Cap
The table below lists competitors of BIOCELTIX S.A. ZY -10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bundamedik Tbk PT
JK:BMHS
|
$89.73 Million |
|
Miwon Holdings Co. Ltd
KO:107590
|
$89.76 Million |
|
Michael Hill International Ltd
AU:MHJ
|
$89.86 Million |
|
MPH Health Care AG
F:93M1
|
$89.91 Million |
|
ADVENICA AB
F:65R
|
$89.73 Million |
|
Q.BEYOND AG NA O.N. KONV.
XETRA:QBY0
|
$89.70 Million |
|
Kino Indonesia Tbk PT
JK:KINO
|
$89.68 Million |
|
Embellence Group AB
ST:EMBELL
|
$89.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BIOCELTIX S.A. ZY -10's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 38,418,105 to 73,276,436, a change of 34,858,331 (90.7%).
- Net loss of 15,159,088 reduced equity.
- New share issuances of 49,658,569 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-15.16 Million | -20.69% |
| Share Issuances | €49.66 Million | +67.77% |
| Other Changes | €358.85K | +0.49% |
| Total Change | €- | 90.73% |
Book Value vs Market Value Analysis
This analysis compares BIOCELTIX S.A. ZY -10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.23x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.95x to 1.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €1.83 | €16.34 | x |
| 2022-12-31 | €1.50 | €16.34 | x |
| 2023-12-31 | €2.53 | €16.34 | x |
| 2024-12-31 | €7.80 | €16.34 | x |
| 2025-12-31 | €13.25 | €16.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BIOCELTIX S.A. ZY -10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (-20.69%) is above the historical average (-87.16%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -73.30% | 0.00% | 0.00x | 1.37x | €-5.00 Million |
| 2022 | -173.20% | 0.00% | 0.00x | 1.49x | €-9.44 Million |
| 2023 | -130.77% | 0.00% | 0.00x | 1.22x | €-14.73 Million |
| 2024 | -37.84% | 0.00% | 0.00x | 1.09x | €-18.38 Million |
| 2025 | -20.69% | 0.00% | 0.00x | 1.03x | €-22.49 Million |
Industry Comparison
This section compares BIOCELTIX S.A. ZY -10's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $355,224,390
- Average return on equity (ROE) among peers: -60.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BIOCELTIX S.A. ZY -10 (XI3) | €73.28 Million | -73.30% | 0.03x | $89.73 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $289.79 Million | -81.80% | 0.17x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $205.51 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.36 Billion | -38.77% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $1.82 Billion |
| BioNTech SE (22UA) | $267.00 Million | -17.98% | 1.45x | $20.05 Billion |
About BIOCELTIX S.A. ZY -10
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells … Read more